Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373

High density synthetic oligonucleotide arrays

Lipshutz, R. J., Fodor, S. P. A., Gingeras, T., & Lockhart, D. J. (1999) · Nature Genetics · doi:10.1038/4447 · Cited by 2,204

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

Stamos, J. L., Sliwkowski, M. X., & Eigenbrot, C. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,594

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Buyse, M. E., Loi, S., Veer, L. V., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian, M., Bergh, J. C. S., Lidereau, R., Ellis, P., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

Mitsudomi, T., & Yatabe, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00607.x · Cited by 606

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 598

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

Mitsudomi, T., & Yatabe, Y. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07448.x · Cited by 560

Array of hope

Lander, E. S. (1999) · Nature Genetics · doi:10.1038/4427 · Cited by 556

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Costa, D. B., Halmos, B., Kumar, A., Schumer, S., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 511

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

Tokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., Ichimura, K., Tsuda, T., Yano, M., Tsukuda, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1167.11.3 · Cited by 489

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463

High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

Buetow, K. H., Edmonson, M. N., MacDonald, R., Clifford, R., Yip, P., Kelley, J. M., Little, D. P., Strausberg, R. L., KOESTER, H., Cantor, C. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.581 · Cited by 459

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Sequist, L. V. D., Besse, B., Lynch, T. J., Miller, V. A., Wong, K., Gitlitz, B. J., Eaton, K. D., Zacharchuk, C., Freyman, A., Powell, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9414 · Cited by 437

Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

Tam, I. Y. S., Chung, L.-P., Suen, W., Wang, E., Wong, M. C. M., Ho, K. K., Lam, W. K., Chiu, S. W., Girard, L., Minna, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1981 · Cited by 400

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A. J., Koutcher, J. A., Spassova, M. K., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 376

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Tarón, M., Ichinose, Y., Rosell, R., Mok, T. S. K., Massutí, B., Zamora, L., Mate, J. L., Manegold, C., Ono, M., Queralt, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2618 · Cited by 332

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Sequist, L. V. D., Gettinger, S. N., Senzer, N. N., Martins, R. G., Janne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 331

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Chou, T., Chiu, C., Li, L., Hsiao, C.-Y., Tzen, C., Chang, K.-T., Chen, Y., Perng, R.-P., Tsai, S., & Tsai, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 315

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

Bean, J. M., Riely, G. J., Balak, M. N., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0151 · Cited by 283

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A. I., Jung, B. L., McNamara, K. L., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 261

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 245

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Linardou, H., Dahabreh, I. J., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 236

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Eck, M. J., & Yun, C.-H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.010 · Cited by 225

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214

Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression

Jiang, J., Greulich, H. E., Janne, P. A., Sellers, W. R., Meyerson, M. M., & Griffin, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1829 · Cited by 188

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1220 · Cited by 181

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y.-L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J., et al. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.010 · Cited by 176

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

Shih, J., Gow, C., Yu, C., Yang, C., Chang, Y., Tsai, M., Hsu, Y., Chen, K., Su, W., & Yang, P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21458 · Cited by 170

Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

Kancha, R. K., von Bubnoff, N., Peschel, C., & Duyster, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1757 · Cited by 168

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160

MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients

Slodkowska, E. A., & Ross, J. S. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.32 · Cited by 159

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

Murray, S. J., Dahabreh, I. J., Linardou, H., Manoloukos, M., Bafaloukos, D. I., & Kosmidis, P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818071f3 · Cited by 154

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138

Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations

Costa, D. B., Schumer, S., Tenen, D. G., & Kobayashi, S. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9039 · Cited by 126

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

Brevet, M., Johnson, M. L., Azzoli, C. G., & Ladanyi, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.014 · Cited by 120

Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance

Kurata, T., Tamura, K., Kaneda, H., Nogami, T., Uejima, H., Asai, G., Nakagawa, K., & Fukuoka, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh006 · Cited by 107

Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

Hata, A., Yoshioka, H., Fujita, S., Kunimasa, K., Kaji, R., Imai, Y., Tomii, K., Iwasaku, M., Nishiyama, A., Ishida, T., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3c5 · Cited by 94

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

Pallis, A. G., Voutsina, A., Kalikaki, A., Souglakos, J., Briasoulis, E. C., Murray, S. J., Koutsopoulos, A. V., Tripaki, M., Stathopoulos, E. N., Mavroudis, D., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604068 · Cited by 90

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

Yuza, Y., Glatt, K. A., Jiang, J., Greulich, H., Minami, Y., Woo, M. S., Shimamura, T., Shapiro, G. I., Lee, J. C., Ji, H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.5.4003 · Cited by 88

Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops

Gazdar, A. F., & Minna, J. D. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0080 · Cited by 88

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

Dufort, S., Richard, M., Lantuéjoul, S., & de Fraipont, F. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-57 · Cited by 84

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

Hsieh, M., Fang, Y., Chang, W.-C., Kuo, H.-P., Lin, S.-Y., Liu, H.-P., Liu, C.-L., Chen, H.-C., Ku, Y.-C., Chen, Y.-T., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.06.005 · Cited by 81

Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer

Coté, M. L., Haddad, R., Edwards, D. J., Atikukke, G., Gadgeel, S. M., Soubani, A. O., Lonardo, F., Bepler, G., Schwartz, A. G., & Ethier, S. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820a0ec0 · Cited by 81

Novel Germline Mutation: EGFR V843I in Patient With Multiple Lung Adenocarcinomas and Family Members With Lung Cancer

Ikeda, K., Nomori, H., Mori, T., Sasaki, J., & Kobayashi, T. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.10.012 · Cited by 73

Familial Lung Adenocarcinoma Caused by the EGFR V843I Germ-Line Mutation

Ohtsuka, K., Ohnishi, H., Kurai, D., Matsushima, S., Morishita, Y., Shinonaga, M., Goto, H., & Watanabe, T. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4492 · Cited by 71

First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer

Wu, J., Yu, C., Yang, C.-H., Wu, S., Chiu, Y., Gow, C., Chang, Y., Hsu, Y.-C., Wei, P., Shih, J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200803-389oc · Cited by 70

Factors associated with long‐term survival of patients with advanced non‐small cell lung cancer

Leprieur, E. G., Lavolé, A., Ruppert, A.-M., Gounant, V., Wislez, M., Cadranel, J. L., & Milleron, B. J. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02070.x · Cited by 54

Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients

Zhang, G., Lin, J.-Y., Wang, Z., Zhou, Q., Xu, C., Zhu, J.-Q., Wang, K., Yang, X.-N., Chen, G., Yang, J.-J., et al. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.04.006 · Cited by 53

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors

Kancha, R. K., Peschel, C., & Duyster, J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182021f3e · Cited by 49

SNaPshot and StripAssay as Valuable Alternatives to Direct Sequencing for KRAS Mutation Detection in Colon Cancer Routine Diagnostics

Sarasqueta, A. F., Moerland, E., de Bruyne, H., de Graaf, H., Vrancken, T., van Lijnschoten, G., & van den Brule, A. J. C. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.006 · Cited by 47

MALDI-TOF MS and TaqMan® assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET)

Jaremko, M., Justenhoven, C., Abraham, B. K., Schroth, W., Fritz, P., Brod, S., Vollmert, C., Illig, T., & Brauch, H. B. (2005) · Human Mutation · doi:10.1002/humu.20141 · Cited by 45

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib

Xu, J., Han, Y., Duan, H. Q., Gao, E., Zhang, Y., Liu, X., Zhang, J. S., Toschi, L., Galetta, D., Azzariti, A., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0512-1 · Cited by 42

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

Harada, T., López-Chávez, A., Xi, L., Raffeld, M. A., Wang, Y., & Giaccone, G. (2010) · Oncogene · doi:10.1038/onc.2010.545 · Cited by 37

Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial

Yang, C., Shih, J.-F., Chao, T., Tsai, C., Yu, C., Yang, P., Streit, M., Shahidi, M., & Miller, V. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8026 · Cited by 32

Integrative computational biology for cancer research

Fortney, K., & Jurišica, I. (2011) · Human Genetics · doi:10.1007/s00439-011-0983-z · Cited by 31

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R

Gow, C., Shih, J., Chang, Y., & Yu, C. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020269 · Cited by 28

A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer

Mol, L., Koopman, M., Ottevanger, P. B., & Punt, C. J. A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp330 · Cited by 13

Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.

Beau‐Faller, M., Prim, N., Ruppert, A.-M., Nanni, I., Besse, B., Escande, F., Lizard, S., Prétet, J., de Crémoux, P., de Fraipont, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.10507 · Cited by 7

Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR.

Costa, D. B., Yasuda, H., Sng, N., Yeo, W.-L., de Figueiredo‐Pontes, L. L., Tenen, D. G., & Kobayashi, S. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7523 · Cited by 6

The ErbB/HER family of protein-tyrosine kinases and cancer

Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,408

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers

Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 502

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021) · Nature · doi:10.1038/s41586-021-03898-1 · Cited by 490

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis

Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 24

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463

Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience

Bonomi, M., Bonomi, L., Sauta, M. G., Bettini, A., Squadroni, M., Brena, F., Cerchiaro, E., Ripa, C., Salvini, P., Beretta, G. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw332.20 · Cited by 1

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors

Wong, K. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70100-4 · Cited by 22